Clinical Curative Effect Of Deanxit Combined With Esomeprazole Magnesium And Mosapride On The Treatment Of Chronic Gastritis

Objective:To discuss the clinical curative effect of deanxit combined with esomeprazole magnesium and mosapride on the treatment of chronic gastritis(CG).Methods:The research subjects were64chronic gastritis outpatients and inpatients of Ji’nan Central Hospital affiliated to Shandong University from September2012to January2014, including30cases of male patients,34female patients, patients aged45-67years old, the average age was58years old. All of them met the standard of the research. All the64patients were divided into experimental group and control group randomly. The experimental group included14male patients and18female patients. The control group included16male patients and16female patients. Through the statistical analysis, the sex and age arrangement of the experimental group and the control group showed no statistically significant (P>0.05). The experimental group members were given deanxit (10.5mg/piece), taken after breakfast and lunch, one piece each time; Esomeprazole Magnesium Enteric-coated Tablets (20mg/piece), taken before breakfast and night sleeping, one piece each time; mosapride (5mg/piece), taken before three meals,2pieces each time. The control group was given Esomeprazole Magnesium Enteric-coated Tablets (20mg/tablets), taken before breakfast and night sleeping, one piece each time; mosapride (5mg/piece), taken before three meals,2pieces each time. The treatment lasted for4weeks. During the treatment patients were prohibited eating excitant food and taking other drugs may affect the test. At the0and4weeks, patients were given the GSRS-C, HAD and EQ-5D evaluation. If the patients had adverse reactions, it would be recorded in details during the entire experiment. Statistical data were analyzed by the SPSS19.0software, the measurement data were presented by the mean number±the standard deviation (x±s), P<0.05mean the significant differences.Results:1. Comparison of GSRS-C score of the two groups at the beginning and end of the treatment.Before the treatment, the experimental group’s GSRS-C score was21.62±4.37,4weeks later the score was7.43±3.52; before the treatment the control group’s GSRS-C score was23.43±5.46,4weeks after the score was14.13±2.51. GSRS-C scores of the two groups were significantly decreased than the beginning(P<0.05), the experimental group’s GSRS-C score was significantly lower than the control group (P<0.05). The curative rate of the experimental group is93.75%, the control group is78.13%. The experimental group’s curative rate was significantly higher than the control group.2. Comparison of HAD score of the two groups at the beginning and end of the treatment.Before the treatment, the experimental group’s HAD (A) score was12.14±4.30,4weeks later the score was4.43±2.62; before the treatment, the experimental group’s HAD (D)score was15.74±3.20,4weeks later the score was6.36±3.81; before the treatment, control group’s HAD(A) score was12.52±4.76,4weeks later the score was8.34±3.61; the control group’s HAD (D) score was15.25±2.85at the beginning of the treatment,4weeks after the score was10.41±4.18. HAD scores of the two groups were significantly decreased than the beginning(P<0.05), the experimental group’s HAD score was significantly lower than the control group (P<0.05).3. Comparison of EQ-5D score of the two groups at the beginning and end of the treatment.Before the treatment, the experimental group’s EQ-VAS score was67.35±3.36,4weeks later the score was87.53±3.74; before the treatment, the experimental group’s EQ-5D score was0.552±0.019,4weeks later the score was0.804±0.021. Before the treatment, the control group’s EQ-VAS score was66.43±4.31,4weeks later the score was76.34±3.61; before the treatment, control group’s EQ-5D score was0.560±0.015,4weeks later the score was0.708±0.022, Two groups’ EQ-VAS, EQ-5D score were significantly increased (P<0.05), the experimental group’s score were much higher than the control group(P<0.05).Conclusions:1. This research shows that esomeprazole magnesium and mosapride can alleviate patients’ digestive tract symptoms and mental disorders. Deanxit combined with esomeprazole magnesium and mosapride has a more significant clinical curative effect on the treatment of chronic gastritis.2. For the chronic gastritis patients accompanied with mental disorder, anti-anxiety and depression therapy combined with conventional treatment can obtain significant effect. Deanxit has a low side effect and a high tolerance.